[New drug approval: Lenvatinib plus pembrolizumab for advanced renal cell carcinoma]
- PMID: 35599170
- DOI: 10.1016/j.bulcan.2022.03.008
[New drug approval: Lenvatinib plus pembrolizumab for advanced renal cell carcinoma]
Keywords: Antibodies Monoclonal; Anticorps monoclonaux; Antineoplastic Agents; Antinéoplasiques; Carcinoma renal cell; Carcinome rénal à cellules claires; Immunotherapy; Immunothérapie.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
